GLENOLDEN, PA — The Charcot-Marie-Tooth Association has committed $100,000 to EverTree Bio, deepening its push to turn early scientific promise into potential treatments for Charcot-Marie-Tooth disease Type 1A, the most common form of the inherited neurological disorder.
The investment follows early testing of EverTree’s therapeutic approach through the CMTA Preclinical Toolbox, a program designed to help researchers and young biotechnology companies generate disease-specific data needed to advance drug development. There are currently no approved treatments for CMT.
EverTree Bio is developing an early-stage therapy aimed at addressing the underlying biology of CMT1A. Its research focuses on restoring glial cell function, promoting myelination—the protective sheath surrounding nerves—and supporting overall nerve health, processes that are disrupted in people living with the disease.
CMTA said the funding reflects its strategy of closing early-stage financing gaps that often stall promising research before it can attract traditional investment. While structured as an investment, the organization described the support as mission-driven and tied directly to patient impact.
“We’re proud to support science that targets the core biology of CMT1A in innovative ways,” said Sue Bruhn, PhD, chief executive officer of CMTA. She said EverTree’s work aligns with the organization’s goal of advancing patient-focused research that might otherwise be overlooked.
EverTree’s relationship with CMTA began through the Preclinical Toolbox, which provides validated disease models and translational tools. Data generated through that collaboration laid the foundation for the company’s current program and the latest funding.
“CMTA has been a key partner from the beginning,” said Sarah Kishinevsky, PhD, co-founder and chief executive officer of EverTree Bio. She said the organization’s early backing helped validate the company’s scientific approach and will now allow it to expand that work.
CMTA said the investment strengthens its broader effort to build a pipeline of viable therapies for CMT by pairing funding with guidance and long-term collaboration. For EverTree, the backing provides critical momentum as it advances an early-stage program in a field where conventional funding remains scarce.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.